House committee advances bill allowing access to non‑FDA experimental treatments after amendments

The House Committee on House Health and Human Services on Tuesday voted to pass Senate Bill 250, a measure that would permit patients to receive certain investigational medical treatments outside established clinical trials, after adopting three amendments intended to tighten informed consent and clarify financial liabilities.

Committee members said the bill is intended to give seriously ill patients another avenue of care for treatments not approved by the U.S. Food and Drug Administration, but several representatives warned the proposal, as originally written, left important questions about consent, DNA or cell use, costs and safeguards unanswered.

Representative Opeza, a committee member who opposed the bill, urged more time for scrutiny and raised ethical concerns about how cells and genetic material collected under the bill might later be used. "This bill does have a consent," Opeza said, "but it never ... state[s] if they should happen to find some wonderful new potential use of these DNA cells that they collect from potential Kansans, how that would be consented for or how that would be used going forward." She said the measure was "very vague" on whether families would be notified or share in any financial benefit resulting from development using a patient's material and concluded, "Unfortunately, I won't be able to support the bill."

Other members voiced related concerns. Representative Bryce and Representative Gardner cautioned that the existing regulatory pathway for drug and biologic approval is slow but provides safeguards; Gardner said the current system "has worked" to bring safe, effective products to market and that desperation should not drive a departure from it. Representative Reese and others emphasized cost and equity issues, noting many treatments described to the committee are expensive and likely out of reach for most patients.

Supporters said the bill fills gaps where U.S. clinical trials are not available. Representative Buehler described cases in which promising treatments are being tested in Europe and said some patients lack domestic options. Representative Droge and Representative Rivas said patients should be allowed to choose such treatments when facing terminal illness.

Three amendments were proposed to address committee concerns. Committee members described the changes on the record as: (1) removing or narrowing a patient attestation requirement that a patient personally demonstrate medical knowledge that all available treatments are unlikely to prolong life and instead relying on informed‑consent elements and medical attestation; (2) requiring that any witness to a patient’s written informed consent be unaffiliated with the treating physician or the entity marketing the treatment; and (3) clarifying that a patient’s estate may be held liable for outstanding treatment debt, to ensure patients understand financial exposure before consenting. Representative Bryce moved the three amendments together; the committee adopted them by voice vote.

After adopting the amendments, the committee voted to pass SB250 "favorably as amended." Representative Buehler moved the committee recommendation; Representative Steens seconded. The committee chair, Representative McDonald, asked for any recorded no votes; Representative McDonald recorded his own no vote. The committee announced the ayes had it and advanced the bill.

Committee discussion referenced testimony and materials offered at a prior hearing; members noted the Kansas Board of Healing Arts had provided neutral testimony and suggested the three amendment concepts. The advisory staff member who helped draft the bill, Jenna Moyer, said she was not aware the bill had been drafted on behalf of a specific manufacturer.

What the bill does and does not do: the committee debate clarified that SB250, as discussed and amended in committee, would allow certain non‑FDA approved treatments outside of regulated clinical trials, subject to written informed consent and physician attestation as amended. The measure does not itself create a state program to pay for treatments, does not require insurers to cover such care, and does not specify any state licensing changes beyond the consent, witness and estate provisions adopted as amendments. Several members urged additional medical testimony and more precise drafting before floor consideration; some said they would nonetheless support the amended bill to preserve patient choice.

Votes at a glance: the committee adopted three amendments by voice vote and then passed SB250 out of committee as amended. Representative McDonald asked to be recorded as opposed; no other recorded no votes were announced.

The committee chair closed the meeting and scheduled further bill work for the following day.